ADHD: Once-Daily INTUNIV Guanfacine Extended Release Tablets Now Available In US Pharmacies
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD. In clinical trials, INTUNIV provided significant efficacy across the spectrum of ADHD symptoms that can be disruptive, such as being easily distracted, interrupting others, running around excessively, arguing with adults, and losing temper.
Shire Reports Findings From An Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse R lisdexamfetamine Dimesylate Capsules
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse® . In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. The post hoc analysis showed that patients demonstrated an improvement in emotional lability composite CPRS-RS scores while taking Vyvanse as compared to placebo. These results were presented recently at a psychiatric meeting in Honolulu.
Queen's And Yale Researchers Win Award For Study That Links Health And Education
Queen's University researcher Steven Lehrer has won a prestigious international award in recognition of his contributions to health economics. A professor in Queen's School of Policy Studies and Department of Economics, Dr. Lehrer shares the RAND Corporation's Victor R. Fuchs Research Award with Jason Fletcher of Yale University. Their prize-winning paper, recently published in the journal Forum for Health Economics & Policy, examines the effects of adolescent health on educational outcomes. "Our study shows that poor mental health in children and teenagers has a large impact on the length of time they will stay in school, " says Dr. Lehrer. He notes a large number of school-based programs have recently been introduced to prevent childhood obesity through lifestyle changes, but suggests the net should be cast more widely.
Shire Reports Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse® . In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. The post hoc analysis showed that patients demonstrated an improvement in emotional lability composite CPRS-RS scores while taking Vyvanse as compared to placebo. These results were presented recently at a psychiatric meeting in Honolulu.